AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3975795 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous saphenous vein grafts
Number of subjects: 77
Study 3975795 — intervention group
Group type: COMPARATOR
Intervention: PTFE grafts
Number of subjects: 77
Study 3975795 — intervention group
Group type: EXPERIMENTAL
Intervention: Both graft materials
Number of subjects: 77
Study 30239007 — intervention group
Group type: EXPERIMENTAL
Intervention: Misogynistic peer norm
Number of subjects: 104
Study 30239007 — intervention group
Group type: COMPARATOR
Intervention: Ambiguous peer norm
Number of subjects: 104
Study 29790073 — intervention group
Group type: EXPERIMENTAL
Intervention: STarT Back risk-stratification strategy
Number of subjects: 6
Study 29790073 — intervention group
Group type: COMPARATOR
Intervention: Control clinics (no training)
Number of subjects: 6
Study 27109453 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 5, 10 or 25 mg
Number of subjects: 68
Study 25011946 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (10-20 µg/day)
Number of subjects: 627
Study 25011946 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro (thrice-daily, titrated to premeal glucose of 5.6-6.0 mmol/L)
Number of subjects: 627
Study 22394386 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive care intervention (PRO) including proactive outreach and choice of smoking cessation services (telephone or face-to-face).
Number of subjects: 0
Study 22394386 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) including access to standard smoking cessation services from VA facility and state telephone quitline.
Number of subjects: 0
Study 20424250 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamin therapy (folic acid 2.5 mg/d, vitamin B(6) 25 mg/d, vitamin B(12) 1 mg/d)
Number of subjects: 238
Study 20424250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 20424250 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamin therapy
Number of subjects: 238
Study 17414234 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (14.2 mg/day)
Number of subjects: 99
Study 17414234 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (7.1 mg/day)
Number of subjects: 99
Study 17414234 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (15.1 mg/day)
Number of subjects: 99
Study 17414234 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (8.5 mg/day)
Number of subjects: 99
Study 17414234 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 99
Study 17414234 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 99
Study 17414234 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfasting glucose levels
Number of subjects: 99
Study 12920661 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulatard insulin
Number of subjects: 60
Study 12920661 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultratard insulin
Number of subjects: 60
Study 11887258 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-needle technique
Number of subjects: 70
Study 11887258 — intervention group
Group type: COMPARATOR
Intervention: One-needle technique
Number of subjects: 70
Study 8812025 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in both analytic and synthetic awareness skills (60 children)
Number of subjects: 100
Study 8812025 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group (40 children)
Number of subjects: 100
Study 1474418 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise
Number of subjects: 0
Study 6141377 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline treatment
Number of subjects: 34
Study 6141377 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 34
Study 30267620 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg/week for 12 weeks)
Number of subjects: 60
Study 28974291 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 450
Study 28974291 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine injection
Number of subjects: 450
Study 28974291 — intervention group
Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 450
Study 25911553 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance (n=338)
Number of subjects: 683
Study 25911553 — intervention group
Group type: COMPARATOR
Intervention: Observation (n=345)
Number of subjects: 683
Study 25911553 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance
Number of subjects: 683
Study 25911553 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 683
Study 25911553 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance in male patients
Number of subjects: 683
Study 25911553 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance in female patients
Number of subjects: 683
Study 23994506 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactose (GAL) CHO drink
Number of subjects: 9
Study 23994506 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (GLU) CHO drink
Number of subjects: 9
Study 23994506 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) drink
Number of subjects: 9
Study 23994506 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO ingestion (GAL, GLU, PLA)
Number of subjects: 9
Study 21875635 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03B-adjuvanted split virion H1N1 vaccine
Number of subjects: 943
Study 21875635 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted whole virion H1N1 vaccine
Number of subjects: 943
Study 18952276 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Esthetic Cement (CEC; Kuraray)
Number of subjects: 18
Study 18952276 — intervention group
Group type: EXPERIMENTAL
Intervention: Rely X Unicem (RXU; 3M ESPE)
Number of subjects: 18
Study 18952276 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibra (CAL; Dentsply Caulk)
Number of subjects: 18
Study 16896167 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretraining trial at 45% Vo(2 max) (45UT)
Number of subjects: 8
Study 16896167 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretraining trial at 65% Vo(2 max) (65UT)
Number of subjects: 8
Study 16896167 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraining trial at 65% of pretraining Vo(2 peak) (ABT)
Number of subjects: 8
Study 16896167 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraining trial at 65% of posttraining Vo(2 peak) (RLT)
Number of subjects: 8
Study 16896167 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg FFA tracer measured uptake during exercise in RLT
Number of subjects: 8
Study 16896167 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg muscle lipid oxidation in ABT
Number of subjects: 8
Study 16896167 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle FFA fractional extraction during exercise
Number of subjects: 8
Study 16896167 — intervention group
Group type: EXPERIMENTAL
Intervention: Training effect on Vo(2 peak)
Number of subjects: 8
Study 14748815 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CYP1A2)
Number of subjects: 12
Study 14748815 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (CYP3A4)
Number of subjects: 12
Study 14748815 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolbutamide (CYP2C9)
Number of subjects: 12
Study 14748815 — intervention group
Group type: EXPERIMENTAL
Intervention: Debrisoquine (CYP2D6)
Number of subjects: 12
Study 14748815 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorzoxazone (CYP2E1)
Number of subjects: 12
Study 14748815 — intervention group
Group type: COMPARATOR
Intervention: Cocktail of all probe drugs
Number of subjects: 12
Study 11109306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocarboxylase (CC) administration, 5 mg/kg body weight, 3 times a week for 12 weeks.
Number of subjects: 35
Study 11109306 — intervention group
Group type: COMPARATOR
Intervention: Control group (mHD, nontreated by CC).
Number of subjects: 35
Study 8993996 — intervention group
Group type: EXPERIMENTAL
Intervention: P300 amplitude
Number of subjects: 0
Study 8993996 — intervention group
Group type: EXPERIMENTAL
Intervention: P300 latency
Number of subjects: 0
Study 8993996 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear relationship
Number of subjects: 0
Study 1309691 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (36 mg daily subcutaneous injection)
Number of subjects: 204
Study 1309691 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 204
Study 1309691 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 204
Study 6329405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg oral tablets
Number of subjects: 103
Study 6329405 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole 100 mg vaginal tablets and 1% cream
Number of subjects: 103
Study 31537233 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled water
Number of subjects: 900
Study 28534190 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal robotic-assisted pyeloplasty
Number of subjects: 80
Study 28534190 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneal robotic-assisted pyeloplasty
Number of subjects: 80
Study 26898494 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical diskectomy
Number of subjects: 748
Study 26898494 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubular-based endoscopic diskectomy
Number of subjects: 748
Study 26898494 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopically assisted microsurgical diskectomy
Number of subjects: 748
Study 26898494 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 748
Study 26056407 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient medication monograph with counseling (PMMC)
Number of subjects: 92
Study 26056407 — intervention group
Group type: COMPARATOR
Intervention: Patient medication monograph only (PMMO)
Number of subjects: 92
Study 22525384 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 57
Study 20518688 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 30
Study 20518688 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 30
Study 17825502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisine
Number of subjects: 0
Study 17825502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15969832 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety advertisements showing drinking and dangerous driving resulting in a crash (experimental group)
Number of subjects: 314
Study 15969832 — intervention group
Group type: COMPARATOR
Intervention: Control group watching advertisements showing people choosing not to drive after drinking
Number of subjects: 314
Study 15969832 — intervention group
Group type: EXPERIMENTAL
Intervention: Self/other comparisons used in both studies
Number of subjects: 314
Study 14575611 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed informed consent regarding the procedure (group A)
Number of subjects: 125
Study 14575611 — intervention group
Group type: COMPARATOR
Intervention: Consent that did not detail specific risks (group B)
Number of subjects: 125
Study 14575611 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 125
Study 14575611 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (before the procedure)
Number of subjects: 125
Study 10378820 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 335
Study 10378820 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 335
Study 10378820 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem XR 200 mg
Number of subjects: 335
Study 10378820 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem XR 300 mg
Number of subjects: 335
Study 10378820 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg
Number of subjects: 335
Study 10378820 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg
Number of subjects: 335
Study 10378820 — intervention group
Group type: COMPARATOR
Intervention: Control (Beta blocker monotherapy)
Number of subjects: 335
Study 8710157 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein restriction intervention
Number of subjects: 456
Study 8710157 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients (mean blood pressure > 107 mmHg)
Number of subjects: 456
Study 8710157 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma creatinine, proteinuria, and plasma calcium
Number of subjects: 456
Study 8710157 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between baseline lying mean blood pressure and proteinuria
Number of subjects: 456
Study 1944967 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 75 micrograms
Number of subjects: 60
Study 1944967 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 micrograms
Number of subjects: 60
Study 1944967 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 60
Study 1944967 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study 31184985 — intervention group
Group type: EXPERIMENTAL
Intervention: Trampoline Training (TT)
Number of subjects: 26
Study 31184985 — intervention group
Group type: COMPARATOR
Intervention: Resistance Training (RT)
Number of subjects: 26
Study 28783884 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern-mixture model approach with multilevel multiple imputation for handling missing data
Number of subjects: 0
Study 28783884 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis using real data from a cluster randomized trial
Number of subjects: 0
Study 25542910 — intervention group
Group type: EXPERIMENTAL
Intervention: Venner‐PneuX ET tube
Number of subjects: 240
Study 25542910 — intervention group
Group type: COMPARATOR
Intervention: Standard ET tube
Number of subjects: 240
Study 23901061 — intervention group
Group type: EXPERIMENTAL
Intervention: m-CIMT + IT (intensive therapy)
Number of subjects: 51
Study 23901061 — intervention group
Group type: COMPARATOR
Intervention: m-CIMT
Number of subjects: 51
Study 21371992 — intervention group
Group type: COMPARATOR
Intervention: Website alone (n = 137)
Number of subjects: 270
Study 21371992 — intervention group
Group type: EXPERIMENTAL
Intervention: Website plus human support (n = 133)
Number of subjects: 270
Study 21371992 — intervention group
Group type: EXPERIMENTAL
Intervention: Website engagement
Number of subjects: 270
Study 20635633 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose beta-carotene supplementation (1.2 mg daily for six months) + Antihelminthic therapy (400 mg albendazole, two doses)
Number of subjects: 244
Study 20635633 — intervention group
Group type: COMPARATOR
Intervention: Antihelminthic therapy (400 mg albendazole, two doses)
Number of subjects: 244
Study 20635633 — intervention group
Group type: COMPARATOR
Intervention: Placebo for beta-carotene + Antihelminthic therapy (400 mg albendazole, two doses)
Number of subjects: 244
Study 20635633 — intervention group
Group type: COMPARATOR
Intervention: Placebo for beta-carotene + Placebo for antihelminthic therapy
Number of subjects: 244
Study 17959988 — intervention group
Group type: EXPERIMENTAL
Intervention: 26-gauge Atraucan spinal needle (n = 52)
Number of subjects: 99
Study 17959988 — intervention group
Group type: COMPARATOR
Intervention: 26-gauge Eldor spinal needle (n = 47)
Number of subjects: 99
Study 16273805 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-dimensional health assessment questionnaire (MDHAQ)
Number of subjects: 0
Study 16273805 — intervention group
Group type: EXPERIMENTAL
Intervention: Health assessment questionnaire (HAQ) and its derivatives
Number of subjects: 0
Study 16273805 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical care without quantitative measures
Number of subjects: 0
Study 12393355 — intervention group
Group type: EXPERIMENTAL
Intervention: FI(O(2)) 1.0 and end‐tidal sevoflurane 2.0% (Group 100)
Number of subjects: 60
Study 12393355 — intervention group
Group type: EXPERIMENTAL
Intervention: FI(O(2)) 0.5 and end‐tidal sevoflurane 1.0% (Group 50)
Number of subjects: 60
Study 12393355 — intervention group
Group type: COMPARATOR
Intervention: FI(O(2)) 0.3 and end‐tidal sevoflurane 0.6% (Group 30)
Number of subjects: 60
Study 10322755 — intervention group
Group type: EXPERIMENTAL
Intervention: Local produced plasma-derived hepatitis B vaccine
Number of subjects: 261
Study 10322755 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 261
Study 7707121 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg clodronate
Number of subjects: 84
Study 7707121 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,600 mg clodronate
Number of subjects: 84
Study 7707121 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,200 mg clodronate
Number of subjects: 84
Study 7707121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 2757911 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (GVG) 1-3 g day-1 for 7 weeks
Number of subjects: 22
Study 2757911 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term GVG therapy (2-4 g day-1) for a mean follow-up of 24 months
Number of subjects: 22
Study 302745 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (vein bypass surgery)
Number of subjects: 1015
Study 302745 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 1015
Study 31326681 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization (staged PCI of all suitable non-culprit lesions plus optimal medical therapy)
Number of subjects: 4041
Study 31326681 — intervention group
Group type: COMPARATOR
Intervention: Culprit lesion-only PCI (optimal medical therapy alone)
Number of subjects: 4041
Study 28682863 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy participants with insomnia symptoms
Number of subjects: 54
Study 28682863 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants without insomnia symptoms
Number of subjects: 54
Study 26008801 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 times per week (G4×)
Number of subjects: 10
Study 26008801 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 times per week (G6×)
Number of subjects: 10
Study 23239872 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 months of exercise at current recommendations for sedentary men
Number of subjects: 44
Study 23239872 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 month of reduced physical activity level (PAL) for normal-weight active men
Number of subjects: 44
Study 23239872 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 month of bed rest with or without exercise for normal-weight women
Number of subjects: 44
Study 23239872 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (exercise)
Number of subjects: 44
Study 23239872 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual physical activity level (PAL)
Number of subjects: 44
Study 21783053 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Choices intervention
Number of subjects: 142
Study 19797252 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrosurgical dissection (EDS)
Number of subjects: 74
Study 19797252 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser extraction
Number of subjects: 74
Study 19797252 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrosurgical dissection (EDS) and Laser extraction
Number of subjects: 74
Study 16797409 — intervention group
Group type: EXPERIMENTAL
Intervention: IST regimen I (E‐ATG alone)
Number of subjects: 142
Study 16797409 — intervention group
Group type: EXPERIMENTAL
Intervention: IST regimen II (E‐ATG and CSA)
Number of subjects: 142
Study 16797409 — intervention group
Group type: EXPERIMENTAL
Intervention: IST regimen III (E‐ATG, CSA, rhuGM‐CSF, rhuEPO)
Number of subjects: 142
Study 16797409 — intervention group
Group type: EXPERIMENTAL
Intervention: IST regimen IV (rabbit ATG (ATG‐F), CSA, rhuGM‐CSF, rhuEPO)
Number of subjects: 142
Study 16797409 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 142
Study 12767410 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 0
Study 12767410 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 0
Study 12767410 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measures over time
Number of subjects: 0
Study 10694834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol 80 mg/day for 5 days
Number of subjects: 27
Study 10694834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol 200 mg/day for 5 days
Number of subjects: 27
Study 10694834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 10694834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol 80 mg/day
Number of subjects: 27
Study 10694834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol 200 mg/day
Number of subjects: 27
Study 9386013 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaching movements with wrist movement allowed (kinematically redundant)
Number of subjects: 60
Study 9386013 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaching movements with wrist restraint (non-redundant)
Number of subjects: 60
Study 8222032 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.75 mg.kg‐1 30 min before separation from parents
Number of subjects: 30
Study 8222032 — intervention group
Group type: COMPARATOR
Intervention: Oral or rectal pentobarbitone 2 mg.kg‐1 at 90 min, and morphine 0.2 mg.kg‐1 and atropine 0.02 mg.kg‐1 im at 60 min before separation
Number of subjects: 30
Study 3776445 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (4 mg) started peroperatively
Number of subjects: 18
Study 3776445 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine (4 mg) started postoperatively
Number of subjects: 18
Study 30224199 — intervention group
Group type: EXPERIMENTAL
Intervention: TIV (full-dose trivalent inactivated influenza vaccine)
Number of subjects: 296
Study 30224199 — intervention group
Group type: EXPERIMENTAL
Intervention: aTIV (adjuvanted trivalent inactivated influenza vaccine)
Number of subjects: 296
Study 30224199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 27260786 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis
Number of subjects: 2